Dashboard
Manage Tickers

NUVLNuvalent, Inc.

Nasdaq nuvalent.com


$ 72.73 $ -2.60 (-3.45 %)    

Tuesday, 02-Jul-2024 12:55:57 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 483.76 $ 3.87 (0.81 %)
DIA $ 390.80 $ -0.04 (-0.01 %)
SPY $ 545.95 $ 2.21 (0.41 %)
TLT $ 90.09 $ -0.58 (-0.64 %)
GLD $ 214.80 $ -0.47 (-0.22 %)
$ 75.51
$ 75.33
$ 0.00 x 0
$ 0.00 x 0
$ 72.19 - $ 75.54
$ 38.78 - $ 89.39
276,984
na
4.84B
$ 1.61
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 02-27-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-16-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-10-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-29-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 09-08-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

novavax-and-agios-pharmaceuticals-were-among-the-10-biggest-mid-cap-gainers-last-week-june-1-june-7-are-these-in-your-portfolio
Novavax And Agios Pharmaceuticals Were Amo...
06/09/2024 18:29:27

Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their ...

wedbush-reiterates-outperform-on-nuvalent-maintains-99-price-target
Wedbush Reiterates Outperform on Nuvalent,...
05/17/2024 13:22:52

Wedbush analyst David Nierengarten reiterates Nuvalent (NASDAQ:NUVL) with a Outperform and maintains $99 price target.

nuvalents-nvl-655-receives-fda-breakthrough-therapy-designation
Nuvalent's NVL-655 Receives FDA Breakthrou...
05/16/2024 20:02:39

nuvalent-q1-2024-gaap-eps-069-misses-068-estimate
Nuvalent Q1 2024 GAAP EPS $(0.69) Misses $...
05/09/2024 10:36:31

Nuvalent (NASDAQ:NUVL) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.68) by...

jefferies-initiates-coverage-on-nuvalent-with-buy-rating-announces-price-target-of-97
Jefferies Initiates Coverage On Nuvalent w...
04/17/2024 11:57:07

Jefferies analyst Roger Song initiates coverage on Nuvalent (NASDAQ:NUVL) with a Buy rating and announces Price Target of $97.

nuvalent-presents-new-preclinical-data-for-her2-selective-inhibitor-nvl-330-and-ros1-selective-inhibitor-zidesamtinib-at-aacr-annual-meeting-2024
Nuvalent Presents New Preclinical Data For...
04/08/2024 20:36:03

Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-typ...

leerink-partners-upgrades-nuvalent-to-outperform-raises-price-target-to-110
Leerink Partners Upgrades Nuvalent to Outp...
04/01/2024 14:57:43

Leerink Partners analyst Andrew Berens upgrades Nuvalent (NASDAQ:NUVL) from Market Perform to Outperform and raises the pric...

jp-morgan-maintains-overweight-on-nuvalent-raises-price-target-to-98
JP Morgan Maintains Overweight on Nuvalent...
03/06/2024 15:58:40

JP Morgan analyst Anupam Rama maintains Nuvalent (NASDAQ:NUVL) with a Overweight and raises the price target from $68 to $98.

guggenheim-assumes-nuvalent-at-buy-announces-price-target-of-99
Guggenheim Assumes Nuvalent at Buy, Announ...
02/28/2024 19:44:49

Guggenheim analyst Kelsey Goodwin assumes Nuvalent (NASDAQ:NUVL) with a Buy rating and announces Price Target of $99.

bmo-capital-maintains-outperform-on-nuvalent-raises-price-target-to-102
BMO Capital Maintains Outperform on Nuvale...
02/28/2024 14:19:06

BMO Capital analyst Etzer Darout maintains Nuvalent (NASDAQ:NUVL) with a Outperform and raises the price target from $93 to ...

recap-nuvalent-q4-earnings
Recap: Nuvalent Q4 Earnings
02/27/2024 13:25:06

nuvalent-q4-eps-062-down-from-049-yoy-cash-balance-of-7199m
Nuvalent Q4 EPS $(0.62) Down From $(0.49) ...
02/27/2024 11:42:10

Nuvalent (NASDAQ:NUVL) reported quarterly losses of $(0.62) per share. This is a 26.53 percent decrease over losses of $(0.49) ...

nuvalent-secures-fda-breakthrough-therapy-designation-for-nvl-520
Nuvalent Secures FDA Breakthrough Therapy ...
02/27/2024 11:17:05

The BTD for NVL-520 is based on the preliminary safety and activity of NVL-520 in heavily pretreated patients with advanced ROS...

baird-initiates-coverage-on-nuvalent-with-outperform-rating-announces-price-target-of-105
Baird Initiates Coverage On Nuvalent with ...
02/23/2024 10:50:00

Baird analyst Colleen Kusy initiates coverage on Nuvalent (NASDAQ:NUVL) with a Outperform rating and announces Price Target ...

nuvalent-has-initiated-phase-2-portion-of-alkove-1-phase-12-trial-of-nvl-655-for-alk-positive-non-small-cell-lung-cancer-and-other-solid-tumors-following-alignment-with-fda-on-recommended-phase-2-dose-of-150-mg-once-daily
Nuvalent Has Initiated Phase 2 Portion Of ...
02/12/2024 11:32:40

nuvalent-announced-its-ontarget-2026-operating-plan-to-guide-efforts-towards-having-its-first-potential-approved-product-in-2026-with-operating-runway-anticipated-into-2027
Nuvalent Announced Its "OnTarget 2026" Ope...
01/08/2024 11:35:07

recap-nuvalent-q3-earnings
Recap: Nuvalent Q3 Earnings
11/14/2023 14:30:13

nuvalent-q3-eps-059-misses-058-estimate-net-proceeds-of-282m-from-public-offering-along-with-cash-cash-equivalents-and-marketable-securities-of-4133m-is-expected-to-extend-operating-runway-into-2027
Nuvalent Q3 EPS $(0.59) Misses $(0.58) Est...
11/14/2023 11:38:03

Nuvalent (NASDAQ:NUVL) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.58) by...

bmo-capital-maintains-outperform-on-nuvalent-raises-price-target-to-79
BMO Capital Maintains Outperform on Nuvale...
10/19/2023 15:49:09

BMO Capital analyst Etzer Darout maintains Nuvalent (NASDAQ:NUVL) with a Outperform and raises the price target from $73 to ...

nuvalent-reports-preliminary-phase-1-clinical-data-from-alkove-1-trial-says-safety-profile-is-consistent-with-an-alk-selective-trk-sparing-design
Nuvalent Reports Preliminary Phase 1 Clini...
10/13/2023 10:31:16

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)
07/16/2024 Vestis Corporation (VSTS)
07/22/2024 Cambium Networks Corporation (CMBM)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)